Wong Grace Lai-Hung, Hui Alex Yui, Wong Vincent Wai-Sun, Chan Francis Ka-Leung, Sung Joseph Jao-Yiu, Chan Henry Lik-Yuen
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Am J Gastroenterol. 2005 Oct;100(10):2205-11. doi: 10.1111/j.1572-0241.2005.50007.x.
Though extensive research has been performed on primary biliary cirrhosis (PBC) in Caucasian patients, little is known about the disease in the Asian population.
This was a retrospective study of Chinese patients with biopsy-proven PBC. Electronic records of results from all liver biopsies (n = 1,021) performed between January 1996 and April 2004, together with records of patients labeled as "biliary cirrhosis," were retrieved. Patients with biopsy-proven PBC were identified, and their medical notes were reviewed. The demographic, clinical, biochemical, and histological parameters of these patients were analyzed for mortality predictors.
Thirty-nine patients with biopsy-proven PBC and a median follow-up of 44 (range: 5-114) months were identified. Twelve patients (30.8%) were asymptomatic at diagnosis. The patients were approximately equally divided into one-thirds at stages I, II, and III of the histological disease. Hepatic decompensation or hepatocellular carcinoma developed in 14 (35.9%) patients during the follow-up period. The overall 5-yr survival probability was 81.4%. Hypoalbuminemia was found to be the only independent predictor of mortality on multivariate analysis (hazard ratio = 0.50 per 1 g/L increase, 95% CI 0.30-0.84, p= 0.008). Using the median serum albumin level as the cutoff, the 5-yr survival probability was significantly higher for patients with serum albumin levels >35 g/L than for those with serum albumin levels < or =35 g/L (100% vs 69%, p= 0.007). No significant difference was found when baseline serum albumin was compared with the Mayo Risk Score and the model for end-stage liver disease (MELD) score for prediction of patient survival (p= 0.68) and death (p= 0.12) at 5 yr.
In this longitudinal cohort study of biopsy-proven PBC with up to 9 yr of follow-up, we found that Chinese patients with PBC had significant morbidity and mortality. Hypoalbuminemia at presentation was an independent and strong predictor of mortality.
尽管对白人原发性胆汁性肝硬化(PBC)患者进行了广泛研究,但对亚洲人群中该疾病的了解甚少。
这是一项对经活检证实为PBC的中国患者的回顾性研究。检索了1996年1月至2004年4月期间所有肝活检(n = 1021)结果的电子记录,以及标记为“胆汁性肝硬化”患者的记录。确定经活检证实为PBC的患者,并查阅其病历。分析这些患者的人口统计学、临床、生化和组织学参数以寻找死亡预测因素。
确定了39例经活检证实为PBC的患者,中位随访时间为44个月(范围:5 - 114个月)。12例患者(30.8%)在诊断时无症状。组织学疾病处于I、II和III期的患者大致各占三分之一。随访期间14例(35.9%)患者出现肝失代偿或肝细胞癌。总体5年生存概率为81.4%。多因素分析发现低白蛋白血症是唯一的死亡独立预测因素(每增加1 g/L,风险比 = 0.50,95% CI 0.30 - 0.84,p = 0.008)。以血清白蛋白水平中位数作为临界值,血清白蛋白水平>35 g/L的患者5年生存概率显著高于血清白蛋白水平≤35 g/L的患者(100%对69%,p = 0.007)。比较基线血清白蛋白与Mayo风险评分及终末期肝病模型(MELD)评分对患者5年生存(p = 0.68)和死亡(p = 0.12)的预测时,未发现显著差异。
在这项对经活检证实为PBC且随访长达9年的纵向队列研究中,我们发现中国PBC患者有显著的发病率和死亡率。就诊时的低白蛋白血症是死亡的独立且有力的预测因素。